



Flu Season 2026 - 2027

What Flu Vaccines Does CCP Offer?

To provide the best protection for patients of all ages, CCP offers age-appropriate flu vaccines. All Community Care primary care offices will be distributing flu vaccine for patients this flu season.

Children (6 months and older): Our pediatric practices offer a flu vaccine approved for children 6 months of age and older called Fluzone Trivalent ([fluzonePIS.pdf](#)).

Adults (18 years and older): For the 2026-2027 flu season, all CCP practices will use Flublok® ([Flu Shot for Ages 9 and Above | Flublok® \(Influenza Vaccine\) | SanofiFluShots](#)) as our standard flu vaccine for adults 18 years of age and older.

Why Did CCP Choose a Different Adult Flu Vaccine?

Each year, CCP's Immunization Action Committee—made up of physicians and pharmacists—reviews the latest medical research and national recommendations before selecting the vaccines offered in our offices.

After carefully reviewing current clinical evidence, the committee selected Flublok as CCP's standard adult flu vaccine because it:

- Provides strong protection against seasonal influenza.
- Has been shown to provide protection comparable to or better than high-dose flu vaccines.
- Is FDA-approved and has been safely used in the United States for more than 10 years and is one of the several influenza vaccines recommended each season.
- Reflects the latest medical evidence and our commitment to providing high-quality patient care.

Our goal remains the same every year: to provide our patients with the best possible protection against the flu.

I Usually Receive the High-Dose Flu Vaccine. Will I Still Be Protected?

Yes. Many adults age 65 and older are familiar with receiving a high-dose flu vaccine. This year, CCP selected a different vaccine because current clinical evidence shows it provides protection comparable to or better than high-dose flu vaccines.

While the vaccine you receive may be different than in previous years, our commitment to protecting your health has not changed. The vaccine selected for this flu season was chosen because it offers excellent protection and is supported by current medical research.

Is Flublok Safe?

Yes. Flublok is an FDA-approved influenza vaccine that has been thoroughly evaluated for safety and effectiveness. It has been available in the United States for more than a decade and has been approved for adults 18 years of age and older since 2014.

Unlike traditional flu vaccines, Flublok is recombinant, meaning it is not made using eggs. Instead, it is produced using recombinant DNA technology, allowing it to more closely match the selected influenza strains. While people with egg allergies can receive any age-appropriate flu vaccine, some patients appreciate that Flublok is not made using eggs.

What Does the Research Show?

CCP's vaccine selection was based on current medical evidence from large clinical studies involving millions of adults.

- Provides better protection than standard-dose flu vaccines.
- Provides protection comparable to or better than high-dose flu vaccines.
- Produces a strong immune response against circulating influenza strains.
- Has been safely used in adults in the United States for more than 10 years.

Our physicians and pharmacists review this evidence each year to ensure the vaccines offered at CCP reflect current medical knowledge and best practices.

Questions?

If you have questions about which flu vaccine is right for you, please talk with your CCP healthcare provider. We're happy to answer your questions and help you make an informed decision about protecting yourself and your family this flu season.

Specific Efficacy Data

1. In a large cluster-randomized study of over 1.6 million adults, Flublok demonstrated 15.3% relative vaccine effectiveness compared to standard-dose vaccines in preventing PCR-confirmed influenza in adults aged 50-64 years ($p=0.002$)
2. Flublok contains three times the hemagglutinin protein content (45 µg per strain) compared to standard-dose vaccines (15 µg per strain), which correlates with enhanced antibody responses
3. The recombinant manufacturing process eliminates egg-based production, preventing antigenic drift during manufacturing and ensuring the vaccine antigen is genetically identical to the selected strain
4. Systematic reviews confirm high-certainty evidence that recombinant vaccines reduce laboratory-confirmed influenza in adults compared to standard vaccines
5. In head-to-head immunogenicity studies, Flublok demonstrated the highest antibody responses to circulating H3N2 strains, particularly against cell-propagated viruses that better represent wild-type strains (mean fold rise 4.7 for Flublok vs. 3.4 for high-dose vaccine)

Hsiao A, Yee A, Fireman B, et al. N Engl J Med 2023;389:2245-2255.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2302099?utm>

Dobrescu AI, Sharifan A, Sommer I, et al. Ann Intern Med. 2026 Jan;179(1):81-94.

<https://pubmed.ncbi.nlm.nih.gov/41248500/>

Belongia EA, Levine MZ, Olaiya O, et al. Vaccine. 2020 Mar 30;38(15):3121-3128.

<https://pubmed.ncbi.nlm.nih.gov/32145994/>